2025³â 03¿ù 29ÀÏ Åä¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýÈ°

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óÇ°

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Korean Research Team Establishes World¡¯s First Tonsil Epithelial Organoids Model for SARS-CoV-2 Infection

World¡¯s First Tonsil Epithelial Organoids Model for SARS-CoV-2 Infection Published in Biomaterials
´º½ºÀÏÀÚ: 2022-04-06

PANGYO-- April 06, 2022 -- The research team led by Professor Jongman Yoo (Cha University and CEO of ORGANOIDSCIENCES) along with Professor Young-Chang Lim (Konkuk University) and Dr. Meehyein Kim (Korea Research Institute of Chemical Technology) successfully established tonsil epithelial cell-derived organoids and proved their feasibility as a 3D cultured infection model.

Organoids, in vitro miniaturized model systems of organs, has been positioned as the most advanced scientific technology for understanding disease progress mechanisms and for discovering novel drugs. However, the generation of tonsil organoids with high reproducibility had remained a technical challenge due to the lack of their cultural system.

This is the first research outcome to the generation of tonsil epithelial organoids, which are structurally and genetically similar to human tonsil tissues, as well as to the scientific assessment of their suitability as an ex vivo model for SARS-CoV-2.

The team showed that the organoids elicit robust expression of transmembrane serine protease 2 (TMPRSS2) and furin, which are important for the maturation of spike proteins, and of the angiotensin-converting enzyme 2 (ACE2) cell surface receptor, which is essential for SARS-CoV-2 infection.

According to the journal, when Remdesivir, an antiviral drug, was applied to tonsil organoids infected with SARS-CoV-2, both viral RNA and protein levels were remarkably reduced. It is expected that the tonsil epithelial organoid could be utilized more extensively as an antiviral drug evaluation system for translational research, particularly against SARS-CoV-2 or its variants.

The results of this study demonstrated that the organoids are an attractive infection model for testing tissue susceptibility or transmissibility of diverse gastrointestinal or respiratory viruses. They provided insight into host defense mechanisms in terms of innate and adaptive immunity in which immunological interactions occur between tonsil epithelial cells, immune cells, and SARS-CoV-2.

The research team said, “Our discovery confirmative suggests that tonsil organoids can be one of the powerful platform technologies to find an antiviral drug against this pandemic virus. We hope our result can be connected to its applications in the research area of infectious diseases threatening public health such as COVID-19.”

On the Biomaterials website, the full research ‘Generation of human tonsil epithelial organoids as an ex vivo model for SARS-CoV-2 infection’ can be found.



 Àüü´º½º¸ñ·ÏÀ¸·Î

Lenovo: Current State of Workplace IT Impedes AI Productivity Benefits
Xsolla Launches Loyalty as a Service for Game Developers to Build Stronger Connections With Players
Toshiba Releases Gate Driver IC for Automotive Brushed DC Motors that Will Contribute to Downsizing of Equipment
Crown Bioscience Appoints John Gu as Chief Executive Officer
Pharmaceutical Industry Issues Call for Collective Action to Address the Rising Global Burden of Chronic Disease
NTT DATA becomes a Global Managed Service Provider in the SAP PartnerEdge, Run Program Track
Caldera Medical Acquires Ethicon¡¯s GYNECARE TVT¢â Family of Products in Transformational Expansion Globally for Women¡¯s Health Company

 

UAE Launches Next-Gen GPS-Less Navigation and Secure Flight Control to...
50% of Asia Pacific Organizations Experience IT or Business Delays Due...
FPT Becomes Sitecore Reseller Partner, Strengthening Strategic Presenc...
Kinaxis to Unveil the Next Phase of AI Innovation at Kinexions 2025
Intersolar Europe: The Time for Hybrid Power Plants Has Come
Xsolla Cloud Gaming Expands Developer Access to New Users With Global ...
Parse Biosciences Expands Global Reach with the South Australian Genom...

 


°øÁö»çÇ×
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®¿ìºê Alliuv ä¹备: ä¹联êó备, ¾Ë¶ã Althle ä¹÷åìÌ
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øü Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¹ÙÀÌ¿ÀÀÌ´Ï Bioini Áß¹® Ç¥±â ù±药研 ù±å·æÚ
¿À½ºÇÁ·Ò Ausfrom 奥ÞÙÜØÙÌ, À£ÇÁ·Ò Welfrom 卫ÜØÙÌ
¿¡³ÊÇÁ·Ò Enerfrom 额ÒöÜØÙÌ ¿¡³ÊÀ¯ºñ Eneruv 额Òöêó备
º£³×ÇÁ·Ò º£³×ÀÎÅõ Áß¹® Ç¥±â 宝Ò¬ÜØÙÌ 宝Ò¬ì×öõ(ÜÄÒ¬ÜØÙÌ ÜÄ...
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØÙÌ ä¹ì³ÜØÙÌ
´º½ºÁö ÇÑÀÚ Ç¥±â¿¡ ´ë¸¸½Ä À½Â÷ Ç¥±â '纽ÞÙó¢ ´Ï¿ì½ÃÁö' º´±â

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æħ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇÑ°è¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, Æѽº 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..